Hansa Biopharma's 2025 Reports Highlight Transformative Growth and Innovation Hansa Biopharma has released its 2025 Annual and Sustainability Reports, emphasizing significant scientific advances and a strong focus on growth amidst leadership changes.

Hansa Biopharma's 2025 Reports Highlight Transformative Growth and Innovation #Sweden #Lund #Hansa_Biopharma #imlifidase #Renée_Aguiar-Lucander

Hansa Biopharma Unveils Transformative Achievements in Its 2025 Annual and Sustainability Reports Hansa Biopharma's 2025 Annual and Sustainability Reports celebrate a year of substantial growth and scientific advancements, reflecting strong progress in healthcare.

Hansa Biopharma Unveils Transformative Achievements in Its 2025 Annual and Sustainability Reports #Sweden #FDA_Approval #Lund #Hansa_Biopharma #imlifidase

Hansa closes on FDA verdict for transplant drug imlifidase The FDA has started reviewing Hansa's imlifidase for highly sensitised adults needing a kidney transplant, but not in the requested rapid timeframe.

The #FDA has started a review of #HansaBiopharma's #imlifidase for patients who need a #kidneytransplant, but for whom finding a donor is particularly challenging, with a decision due before the end of the year.

pharmaphorum.com/news/hansa-c...

Hansa Biopharma's Imlifidase BLA Receives PDUFA Date of December 2026 Hansa Biopharma announces the PDUFA action date for imlifidase, set for December 19, 2026, signaling progress for kidney transplant options.

Hansa Biopharma's Imlifidase BLA Receives PDUFA Date of December 2026 #Sweden #FDA_Approval #Lund #Hansa_Biopharma #imlifidase

Hansa Biopharma's Imlifidase BLA Receives PDUFA Date for December 2026 Hansa Biopharma's Imlifidase BLA is set for PDUFA review by the FDA on December 19, 2026, marking a significant step for kidney transplant patients.

Hansa Biopharma's Imlifidase BLA Receives PDUFA Date for December 2026 #Sweden #Lund #Hansa_Biopharma #imlifidase #IDEFIRIX

Hansa Biopharma's FDA Acceptance for Innovative Imlifidase Marks a Milestone in Kidney Transplant Treatments Hansa Biopharma's biologics license application for Imlifidase has been accepted by the FDA, opening new avenues for kidney transplantation.

Hansa Biopharma's FDA Acceptance for Innovative Imlifidase Marks a Milestone in Kidney Transplant Treatments #Sweden #FDA_Approval #Lund #Hansa_Biopharma #imlifidase

Hansa Biopharma's Innovative Imlifidase Receives FDA Acceptance for BLA Hansa Biopharma's biologics license application for imlifidase has been accepted by the FDA, marking a significant step for kidney transplantation treatments.

Hansa Biopharma's Innovative Imlifidase Receives FDA Acceptance for BLA #USA #FDA_Approval #Lund #Hansa_Biopharma #imlifidase

Hansa Biopharma's Remarkable Financial Growth in 2025 Explained Hansa Biopharma AB reports significant financial growth in Q4 and full-year 2025, reinforcing its position in biopharmaceutical innovation.

Hansa Biopharma's Remarkable Financial Growth in 2025 Explained #Sweden #financial_results #Lund #Hansa_Biopharma #imlifidase

Hansa Biopharma Honored with the 2025 SwedenBIO Award for Groundbreaking Innovations Hansa Biopharma has been awarded the prestigious 2025 SwedenBIO Award, recognizing its significant contributions to medical science and patient care.

Hansa Biopharma Honored with the 2025 SwedenBIO Award for Groundbreaking Innovations #Sweden #Lund #Hansa_Biopharma #imlifidase #SwedenBIO

Hansa Biopharma Files for FDA Approval of Imlifidase to Aid Kidney Transplant Patients Hansa Biopharma has submitted a Biologics License Application to the FDA for Imlifidase, designed to help heavily sensitized kidney transplant patients. This therapy could revolutionize patient options.

Hansa Biopharma Files for FDA Approval of Imlifidase to Aid Kidney Transplant Patients #Sweden #Lund #kidney_transplant #Hansa_Biopharma #imlifidase

Hansa Biopharma's Application for Imlifidase Could Transform Kidney Transplantation for Sensitized Patients Hansa Biopharma has submitted a Biologics License Application for Imlifidase, potentially changing the game for highly sensitized kidney transplant patients in the U.S.

Hansa Biopharma's Application for Imlifidase Could Transform Kidney Transplantation for Sensitized Patients #USA #Lund #Hansa_Biopharma #imlifidase #kidney_transplantation

Our recording of an excellent and educational rounds by Dominique Bertrand from Rouen is now live

www.youtube.com/watch?v=xUx3...

#Transplantation in highly sensitized recipients, with the #imlifidase experience in particular!

Significant Growth Expected in Antibody-Mediated Rejection Market by 2034 Driven by New Therapeutics The antibody-mediated rejection market is set for robust expansion over the next decade, as advances in treatment and diagnostics support increased transplant success.

Significant Growth Expected in Antibody-Mediated Rejection Market by 2034 Driven by New Therapeutics #None #imlifidase #Antibody-mediated_Rejection #Felzartamab

Hansa’ Imlifidase Reduce Anti-AAV Antibodies and Allow Administration of Gene Therapy Two gene therapy trials, one sponsored by Sarepta and the other sponsored by Genethon, support the ability of imlifidase to substantially reduce anti-AAV antibodies to allow administration of gene therapy.

Hansa’ Imlifidase Reduce Anti-AAV Antibodies and Allow Administration of Gene Therapy

#dmd #duchenne #imlifidase #genetherapy #clinicaltrials

👉 Read More: DMDWarrioR.com

Hansa Biopharma Unveils Third Quarter Financial Results for 2025 Hansa Biopharma announces its financial report for Q3 2025, showcasing significant milestones in kidney transplantation and promising growth in product sales.

Hansa Biopharma Unveils Third Quarter Financial Results for 2025 #Sweden #Lund #Hansa_Biopharma #imlifidase #ConfIdeS_Trial

Hansa Biopharma Achieves Key Milestone in Kidney Transplantation with Imlifidase Hansa Biopharma recently reported strong interim financial results for 2025, showcasing their groundbreaking treatment Imlifidase in kidney transplantation.

Hansa Biopharma Achieves Key Milestone in Kidney Transplantation with Imlifidase #Sweden #Lund #Hansa_Biopharma #imlifidase #kidney_transplantation

Hansa Biopharma Hosts Virtual Event with Renowned Transplant Surgeons Focusing on Imlifidase Phase 3 Results Join Hansa Biopharma for an insightful session featuring leading transplant surgeons discussing the Phase 3 results of Imlifidase, a novel treatment for transplant patients.

Hansa Biopharma Hosts Virtual Event with Renowned Transplant Surgeons Focusing on Imlifidase Phase 3 Results #Sweden #Lund #Hansa_Biopharma #imlifidase #Transplant_Surgeons

Hansa Biopharma Hosts Virtual Event with Leading Transplant Surgeons to Discuss Imlifidase Phase 3 Results Hansa Biopharma's upcoming virtual event on November 12, 2025, will involve insights from top transplant surgeons regarding the Phase 3 results of imlifidase.

Hansa Biopharma Hosts Virtual Event with Leading Transplant Surgeons to Discuss Imlifidase Phase 3 Results #Sweden #Lund #Hansa_Biopharma #imlifidase #Transplant_Surgeons

Every now and then, I come across #Imlifidase again, an enzyme capable of cleaving circulating and bound IgG antibodies.
1/4

Imlifidase Shows Promising Results in Critical Phase 3 Kidney Transplant Trial Hansa Biopharma's imlifidase meets primary endpoint in US Phase 3 ConfIdeS trial, benefitting kidney transplantation for highly sensitized patients.

Imlifidase Shows Promising Results in Critical Phase 3 Kidney Transplant Trial #USA #Lund #Hansa_Biopharma #imlifidase #ConfIdeS_Trial

Hansa Biopharma Reveals Promising Five-Year Data on Imlifidase in Kidney Transplants at ESOT 2025 At the ESOT Congress 2025, Hansa Biopharma presented five-year results from its imlifidase study, signaling great potential for kidney transplant success in sensitized patients.

Hansa Biopharma Reveals Promising Five-Year Data on Imlifidase in Kidney Transplants at ESOT 2025 #Sweden #Lund #kidney_transplant #Hansa_Biopharma #imlifidase

Hansa Biopharma Unveils Five-Year Follow-Up Results for Imlifidase in Kidney Transplants at ESOT 2025 Hansa Biopharma showcases exciting five-year data on imlifidase for kidney transplants, demonstrating promising patient outcomes at ESOT 2025 in London.

Hansa Biopharma Unveils Five-Year Follow-Up Results for Imlifidase in Kidney Transplants at ESOT 2025 #Sweden #London #Hansa_Biopharma #imlifidase #ESOT_Congress

Hansa Biopharma Unveils Promising Findings on Imlifidase for Guillain-Barré Syndrome at 2025 PNS Annual Meeting At the 2025 PNS Annual Meeting in Edinburgh, Hansa Biopharma reveals groundbreaking data on imlifidase's effectiveness for Guillain-Barré Syndrome treatment, showcasing its potential.

Hansa Biopharma Unveils Promising Findings on Imlifidase for Guillain-Barré Syndrome at 2025 PNS Annual Meeting #Sweden #Lund #Hansa_Biopharma #imlifidase #GBS_Treatment

Hansa Biopharma Showcases Imlifidase's Promise in Guillain-Barré Syndrome at 2025 PNS Meeting At the 2025 PNS Annual Meeting, Hansa Biopharma unveiled promising data on imlifidase, showcasing its potential in treating Guillain-Barré Syndrome.

Hansa Biopharma Showcases Imlifidase's Promise in Guillain-Barré Syndrome at 2025 PNS Meeting #Sweden #Lund #Hansa_Biopharma #imlifidase #Guillain-Barré

Hansa Biopharma Set to Showcase Innovations at 2025 J.P. Morgan Healthcare Conference Hansa Biopharma has announced its participation in the 2025 J.P. Morgan Healthcare Conference, showcasing advancements in autoimmune and gene therapy.

Hansa Biopharma Set to Showcase Innovations at 2025 J.P. Morgan Healthcare Conference #Sweden #gene_therapy #Lund #Hansa_Biopharma #imlifidase

Hansa Biopharma to Participate in the 2025 J.P. Morgan Healthcare Conference Hansa Biopharma is set to attend the 43rd Annual J.P. Morgan Healthcare Conference, showcasing recent advancements in therapies for autoimmune diseases.

Hansa Biopharma to Participate in the 2025 J.P. Morgan Healthcare Conference #Sweden #gene_therapy #Lund #Hansa_Biopharma #imlifidase

Hansa Biopharma's Breakthrough Results in Phase 2 Study of Imlifidase for Guillain-Barré Syndrome Hansa Biopharma shares promising findings from its Phase 2 study of imlifidase for treating Guillain-Barré Syndrome, highlighting faster recovery times and improved patient outcomes.

Hansa Biopharma's Breakthrough Results in Phase 2 Study of Imlifidase for Guillain-Barré Syndrome #Sweden #Lund #Hansa_Biopharma #imlifidase #Guillain-Barré_Syndrome

Hansa Biopharma Reveals Promising Phase 2 Trial Results for Imlifidase in Guillain-Barré Syndrome Treatment Hansa Biopharma announces positive outcomes from its Phase 2 trial of Imlifidase for treating Guillain-Barré Syndrome, showcasing improved patient recovery timelines.

Hansa Biopharma Reveals Promising Phase 2 Trial Results for Imlifidase in Guillain-Barré Syndrome Treatment #Sweden #Lund #Hansa_Biopharma #imlifidase #Guillain-Barré

Hansa Biopharma Achieves Patient Enrollment Completion in Key Phase 3 Trial for Imlifidase Hansa Biopharma has successfully registered all patients for its pivotal GOOD-IDES-02 trial, investigating imlifidase for treating anti-GBM disease. Results expected in 2025.

Hansa Biopharma Achieves Patient Enrollment Completion in Key Phase 3 Trial for Imlifidase #Sweden #Lund #Hansa_Biopharma #imlifidase #Anti-GBM

Hansa Biopharma Completes Patient Enrollment in Pivotal Trial for Imlifidase in Treating Rare Autoimmune Disease Hansa Biopharma has successfully completed patient enrollment in the pivotal GOOD-IDES-02 trial for imlifidase, targeting anti-glomerular basement membrane disease, a rare autoimmune condition.

Hansa Biopharma Completes Patient Enrollment in Pivotal Trial for Imlifidase in Treating Rare Autoimmune Disease #Sweden #Lund #Hansa_Biopharma #imlifidase #Autoimmune_Disease